Author

E. Criscuolo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:microscopy & imaging analysis· 2

Frequent Co-Authors

N. Mancini· 6 shared N. Clementi· 5 shared M. Clementi· 4 shared M. Castelli· 3 shared R. A. Diotti· 3 shared R. Burioni· 2 shared A. Challis· 1 shared A. Conforti· 1 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

N. Mancini

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

SARS-CoV-2 Spike Affinity and Dynamics Exclude the Strict Requirement of an Intermediate Host

M. Castelli, L. Scietti, N. Clementi, M. Cavallaro, S. Faravelli, A. Pinnola, E. Criscuolo, R. A. Diotti, M. Clementi, F. Forneris, N. Mancini

This study shows SARS-CoV-2 and RaTG13 spikes have similar ACE2 binding affinities, suggesting minimal species barriers, and highlights SARS-CoV-2's optimized dynamics for human ACE2 engagement.

bioRxiv · Aug 11, 2021 · PreprintMicrobiology

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

A. Conforti, E. Marra, F. Palombo, G. Roscilli, M. Rava, V. Fumagalli, A. Muzi, M. Maffei, L. Luberto, L. Lione, E. Salvatori, M. Compagnone, E. Pinto, E. Pavoni, F. Bucci, , De F

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.

bioRxiv · Jun 14, 2021 · PreprintImmunology

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection

M. Severa, R. A. Diotti, M. P. Etna, F. Rizzo, S. Fiore, D. Ricci, M. Iannetta, A. Sinigaglia, A. Lodi, N. Mancini, E. Criscuolo, M. Clementi, M. Andreoni, S. Balducci, L. Barzon, , E. Coccia

This study compares plasmacytoid dendritic cell (pDC) phenotype and type I IFN response in asymptomatic and severe COVID-19 patients, finding differences in pDC frequency, phenotype, and cytokine levels.

bioRxiv · Apr 17, 2021Immunology

A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells

B. Storti, P. Quaranta, C. Di Primio, N. Clementi, N. Mancini, E. Criscuolo, P. G. Spezia, V. Carnicelli, G. Lottini, E. Paolini, G. Freer, M. Lai, M. Costa, F. Beltram, A. Diaspro, , R. Bizzarri

The paper uses multi-scale fluorescence microscopy to study SARS-CoV-2 variant entry into Vero E6 cells, finding B.1.1.7 enters faster than its ancestor due to the N501Y mutation.

bioRxiv · Mar 31, 2021Biophysics

A human stem cell-derived neurosensory-epithelial circuitry on-a-chip to model herpes simplex virus reactivation

P. G. Mazzara, E. Criscuolo, M. Rasponi, L. Massimino, S. Muggeo, C. Palma, M. Castelli, M. Clementi, R. Burioni, N. Mancini, V. Broccoli, N. Clementi

This study develops a human stem cell-derived neurosensory-epithelial circuitry on-a-chip to model HSV-1 reactivation and latency.

bioRxiv · Nov 19, 2020Microbiology

Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro

N. Clementi, E. Criscuolo, R. A. Diotti, R. Ferrarese, M. Castelli, R. Burioni, M. Clementi, N. Mancini

This study shows that hydroxychloroquine is most effective against SARS-CoV-2 when used both before and after infection in vitro.

bioRxiv · Mar 29, 2020Microbiology